Oncology Archives - Insights

Mayo Clinic Laboratories and Lucence announce strategic collaboration to enhance cancer testing services

Mayo Clinic Laboratories — Fri, 10 Jan 2025 17:30:00 +0000

Mayo Clinic Laboratories and Lucence are expanding access to advanced cancer testing worldwide with LiquidHALLMARK®, a next-generation liquid biopsy that provides actionable genomic insights. This collaboration empowers physicians to deliver personalized care and improve patient outcomes.

The post Mayo Clinic Laboratories and Lucence announce strategic collaboration to enhance cancer testing services appeared first on Insights.

Genetic Tests Identify Risk of Irinotecan-Induced Toxicity: John Logan Black, M.D.

Barbara J. Toman — Tue, 12 Nov 2024 14:00:00 +0000

John Logan Black, M.D., explains how Mayo Clinic Laboratories' UGT1A1 tests (Mayo IDs: U1A1Q and UGTFZ) identify genetic variants that increase the risk of potentially life-threatening reactions to irinotecan, a chemotherapy agent.

The post Genetic Tests Identify Risk of Irinotecan-Induced Toxicity: John Logan Black, M.D. appeared first on Insights.

Fergus Couch, Ph.D., co-authors new guidelines for interpreting ATM cancer gene variants

Cory Pedersen — Mon, 11 Nov 2024 14:00:00 +0000

Fergus Couch, Ph.D., chair of Mayo Clinic’s Division of Experimental Pathology and Laboratory Medicine, led a team that recently published new National Institutes of Health and U.S. Food and Drug Administration-approved guidelines for the interpretation of variants in the ataxia telangiectasia mutated (ATM) cancer gene. Inherited mutations in ATM have been shown to increase the risk of breast, pancreatic, and prostate cancers. Now published by the American Journal of Human Genetics and available for widespread use, Dr. Couch says the guidelines can help clinicians around the world apply the same consistent method of classification to ATM variants.

The post Fergus Couch, Ph.D., co-authors new guidelines for interpreting ATM cancer gene variants appeared first on Insights.

Dr. Dong Chen and Dr. Sounak Gupta join Becker’s Healthcare Podcast to discuss molecular testing in cancer care

jgilligan1 — Tue, 29 Oct 2024 01:00:00 +0000

Dr. Dong Chen and Dr. Sounak Gupta joined the “Becker’s Healthcare Podcast” to discuss the molecular testing space and its important role in personalized cancer treatment. Dr. Chen and Dr. Gupta highlighted the importance of selecting the right molecular tests for patients, the impact of genetic testing on cancer diagnosis and treatment, and how Mayo Clinic Laboratories is helping physicians make informed decisions for the best patient outcomes.

The post Dr. Dong Chen and Dr. Sounak Gupta join Becker’s Healthcare Podcast to discuss molecular testing in cancer care appeared first on Insights.

Hypermethylation Test Guides Lynch Syndrome Care: Megan Hoenig, M.S., M.P.H., CGC

Barbara J. Toman — Tue, 22 Oct 2024 13:00:00 +0000

Megan Hoenig, M.S., M.P.H., CGC, explains how Mayo Clinic Laboratories' unique hypermethylation analysis (Mayo ID: MLHPB) provides critical adjunct information for managing Lynch syndrome. That genetic condition increases the risk for many kinds of cancer.

The post Hypermethylation Test Guides Lynch Syndrome Care: Megan Hoenig, M.S., M.P.H., CGC appeared first on Insights.

Optimizing Cancer Care: ASCO Guidelines for Germline Genetic Testing

MCL Education — Wed, 09 Oct 2024 12:00:00 +0000

PACE / State of FL- Presentation Recording Coming Soon
This webinar will delve into the latest ASCO guidelines for selection of germline genetic testing panels for cancer patients. Key topics include the importance of taking and recording a detailed family and personal history, selecting the appropriate genes for testing, and determining when and to whom germline testing should be offered. The session will also address the practical implications of the ASCO guidelines, such as balancing the potential benefits of broader gene panel testing with the risks associated with uncertain results. Additionally, participants will gain insights into the specific technical challenges associated with germline genetic testing in cancer care and risk management.

The post Optimizing Cancer Care: ASCO Guidelines for Germline Genetic Testing appeared first on Insights.

Advanced Diagnostics Laboratory helps improve the way oncologists treat patients through development of the Mayo Complete Solid Tumor Panel

Chris Bahnsen — Wed, 25 Sep 2024 13:00:00 +0000

Founded in 2017, Mayo Clinic's Advanced Diagnostics Laboratory is a visionary space. In 2021, the lab developed the Mayo Complete Solid Tumor Panel, a clinically validated assay that analyzes 515 genes using next-generation sequencing. This multiple test panel, the first of its kind at Mayo, aids in selecting targeted therapies, diagnosing tumor types, and predicting prognosis, significantly improving patient care.

The post Advanced Diagnostics Laboratory helps improve the way oncologists treat patients through development of the Mayo Complete Solid Tumor Panel appeared first on Insights.

A shared journey through breast cancer: Samantha Duke and Jane Hanson

Robin Huiras-Carlson — Mon, 23 Sep 2024 13:00:00 +0000

When Samantha Duke discovered she had breast cancer, she didn’t have to look far for support. Her mother Jane walked a similar path 16 years earlier. Inspired both by her mom and the strong network of healthcare physicians and professionals on her team, Samantha remained positive throughout her treatment and is committed to advancing research on breast cancer.

The post A shared journey through breast cancer: Samantha Duke and Jane Hanson appeared first on Insights.

Thermo Fisher Scientific: Illuminating rare cancer prognosis and improving patients’ lives

Robin Huiras-Carlson — Mon, 16 Sep 2024 13:00:00 +0000

Aiming to advance understanding of hard-to-predict gastroenteropancreatic neuroendocrine tumors (GEP-NETs), Thermo Fisher Scientific joined forces with Mayo Clinic and BioPharma Diagnostics to validate and gain U.S. regulatory clearance of a novel, automated assay aimed at detecting a biomarker associated with the progressive disease.

The post Thermo Fisher Scientific: Illuminating rare cancer prognosis and improving patients’ lives appeared first on Insights.

Enhanced Solid Tumor NGS Panel Broadens Genetic-Variants Detection: Robert Jenkins, M.D., Ph.D., Stephanie Smoley, CG(ASCP), and Beth Pitel, M.S.

Barbara J. Toman — Tue, 21 May 2024 13:00:00 +0000

Robert Jenkins, M.D., Ph.D., Stephanie Smoley, CG(ASCP), and Beth Pitel, M.S., explain how Mayo Clinic Laboratories' enhanced MayoComplete Solid Tumor Panel better profiles tumor genetics. Defining tumor pathogenesis can guide targeted cancer therapy.

The post Enhanced Solid Tumor NGS Panel Broadens Genetic-Variants Detection: Robert Jenkins, M.D., Ph.D., Stephanie Smoley, CG(ASCP), and Beth Pitel, M.S. appeared first on Insights.